Skip to main content

Table 1 Effector and processing based on HDAC6 deacetylation activity of Hsp90

From: Posttranslational modification and beyond: interplay between histone deacetylase 6 and heat-shock protein 90

Effector or client protein of Hsp90 Biological process or pathway Intervention method of HDAC6 References
GR Glucocorticoid receptor maturation in A431, A549 cells or serotonin pathways in mice Mutations, trichostatin A (TSA) (1 μM), Tubacin (10 μM), ACY-738(2.5 μM) knock out or transgenesis Espallergues et al. (2012); Hu et al. (2019); Jochems et al. (2015); Kovacs et al. (2005a, b); Lee et al. (2012); Murphy et al. (2005); Zhu et al. (2020)
ERα Hippo pathway in ERα + or tamoxifen-resistant breast cancer Tubacin (1 μM), Panobinostat (LBH589) (100 nM) or Dacinostat (LAQ824) (250 nM) Fiskus et al. (2007); Yu et al. (2017)
HIF-1α Glioblastoma growth and angiogenesis LBH589 (40 nM) or TSA (500 nM) Schoepflin et al. (2016); Yao et al. (2017); Zhang et al. (2010)
EGFR Esophageal squamous cell carcinoma proliferation and migration siRNA or Tubastatin (1 μM) Tao et al. (2018); Kim et al. (2009); Gravina et al. (2013)
Kit Growth inhibition, cell cycle arrest, apoptosis against malignant mast cell lines AR-42 (3 μM) Lin et al. (2010)
Her-2 Her-2 stability via the proteasome pathway in SK-BR-3 cells Carbamazepine (CBZ) (100 μM) or TSA) (100 nM) Kim et al. (2009); Gravina et al. (2013); Meng et al. (2011)
VEGFRs Proteasomal degradation of vascular endothelial growth factor receptors Suberoylanilide hydroxamic acid (SAHA) (1 μM), LAQ824 (300 nM) or TSA (30 nM) or Tubacin (100 nM) Park et al. (2008); Verheyen et al. (2012)
AR Proteasome degradation of AR in LNCaP cells or prostate cancer siRNA, overexpression, genistein (25 μM), 4-HBAs (4-hydroxybenzoic acids) (50 μM), SAHA (10 μM), Sulforaphane (20 μM), Belinostat (PXD101) (0.5 μM) or 2‐75 (2.5 µM) Hu et al. (2019); Gravina et al. (2013); Ai et al. (2009); Basak et al. (2008); Gibbs et al. (2009); Rosati et al. (2016); Seidel et al. (2016)
AhR Aryl hydrocarbon receptor signaling in human aerodigestive epithelial cells TSA (500 nM), SAHA (20 μM) or Tubacin (20 μM) Kekatpure et al. (2009)
Rac1 Membrane ruffle formation and cell migration in MEFs knock-out HDAC6 Gao et al. (2007)
Survivin Autophagy and viability reduction in breast cancer cells SAHA (1.4 μM) Lee et al. (2016)
Bcr-Abl Degradation of Bcr-Abl in human leukemia cells or FDCP-1 cells LAQ824(100 nM), SAHA (5 μM), MRLB-223(10 μM) or siRNA Rao et al. (2008); Bali et al. (2005); Lee et al. (2007); Newbold et al. (2013)
c-Raf Degradation of c-Raf human in leukemia cells Tubacin (3 µM) and siRNA Rao et al. (2008)
tau Degradation of tau in HEK293T or HeLa cells and tau pathology neurodegeneration in rTg4510 mouse models Overexpression HDAC6, siRNA or tubastatin (25 mg/kg/day) Selenica et al. (2014); Cook et al. (2012)
aurora-A Migration and metastatic activity in breast cancer MPT0G211 (10 μM) or tubastatin A (10 μM) Hsieh et al. (2019)
IKKα Proliferation and apoptosis in human myeloma cell line and primary myeloma cells As2O3(5 μM) Qu et al. (2012)
MIF MIF stability via the proteasome pathway in cancer cells siRNA or SAHA (5 μM) Schulz et al. (2012)
cyclin D1 and CDK4 G1 growth arrest in lung cancer cells NBM-T-BBX-OS01 (10 μM) or overexpression Pai et al. (2015)
mutant p53 Preferential cytotoxicity for mutp53 tumor SAHA (5 μM), siRNA, or A452(2 μM) Li et al. (2011); Ryu et al. (2017b)
MMP-9 Migration and invasion activities in lung cancer Honokiol (10 μM) Pai et al. (2020)
NS5(Japanese Encephalitis Virus) Viral RNA Synthesis Tubacin (10 μM) or TBSA (10 μM) Lu et al. (2017)